Frontiers in immunology · 2025
Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia.
СтатьяКлиническое исследование II фазыНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Hui-Sheng, Su Yong-Feng, Wang Jun, Hu Ya-Lei, Wang An, Xu Lei, Wang Yi-Zhi, Zheng Xuan, Li Yu-Qing, Min Kai-Li, Gao Chun-Ji, Liu Dai-Hong, Gao Xiao-Ning
Аннотация
INTRODUCTION: Anti-PD-1 monotherapy has shown limited clinical efficacy in patients with relapsed/refractory acute myeloid leukemia (r/r AML). Our study aimed to analyze the effectiveness and safety of combining tislelizumab with a hypomethylating agent (HMA) plus CAG regimen in treating patients with r/r AML, with an increased sample size and in comparison, with a historical control group for more reliable data support (ClinicalTrials.gov identifier NCT04541277).
METHODS: The study included a total of 37 patients with r/r AML who received the tislelizumab + HMA + CAG regimen.
RESULTS: The overall response rate was 69.4%, with a median overall survival of 12.1 months and event-free survival of 6.2 months. Multivariate analysis revealed that patients aged 40 or above exhibited a higher response rate, while those with lower leukemia burden (bone marrow blast percentage <40%) demonstrated improved overall survival and event-free survival. Additionally, bridging allogeneic hematopoietic stem cell transplantation was associated with extended event-free survival. Grade 2-3 immune-related adverse events were observed in 8.5% of patients, and no deaths were directly attributed to these events. After propensity score matching, the inclusion of tislelizumab appeared to positively influence the overall response rate and event-free survival compared to historical controls treated with HMA + CAG regimen.
DISCUSSION: Overall, the combination regimen improved response rates while maintaining low incidence and severity of immune-related adverse events for r/r AML patients.
CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/, identifier NCT04541277.
METHODS: The study included a total of 37 patients with r/r AML who received the tislelizumab + HMA + CAG regimen.
RESULTS: The overall response rate was 69.4%, with a median overall survival of 12.1 months and event-free survival of 6.2 months. Multivariate analysis revealed that patients aged 40 or above exhibited a higher response rate, while those with lower leukemia burden (bone marrow blast percentage <40%) demonstrated improved overall survival and event-free survival. Additionally, bridging allogeneic hematopoietic stem cell transplantation was associated with extended event-free survival. Grade 2-3 immune-related adverse events were observed in 8.5% of patients, and no deaths were directly attributed to these events. After propensity score matching, the inclusion of tislelizumab appeared to positively influence the overall response rate and event-free survival compared to historical controls treated with HMA + CAG regimen.
DISCUSSION: Overall, the combination regimen improved response rates while maintaining low incidence and severity of immune-related adverse events for r/r AML patients.
CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/, identifier NCT04541277.